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ABSTRACT
The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2, or
SARS-CoV-2, has been ongoing for over two years. The virus spreads easily and is more
unpredictable than well-known viruses like the flu, making it important to have reliable combative
measures before we fully drop non-vaccine preventive actions, like mask-wearing.Therefore, we
used computational protein modeling to investigate the interactions of three nonstructural proteins
(abbreviated Nsp) encoded in the viral RNA genome– Nsp3, Nsp5, and Nsp6 – which are involved
in the viral life cycle, with human P-type polyamine transporting ATPases ATP13A2 and
ATP13A3, whose disease symptoms when mutated mimic certain COVID-19 complications.
Understanding these interactions can help shed light on the mechanism of unexpected symptoms
seen in COVID-19 and provide an avenue through which to treat infections. Additionally, papainlike protease (PLpro) and 3-chymotrypsin-like protease (3CLpro), which correspond to Nsp3 and
Nsp5, respectively, are highly conserved between SARS-CoV and SARS-CoV-2 and thus make
good potential drug targets due to their active sites and presumable lower ability to tolerate
mutations (reducing the likelihood of treatments becoming ineffective), although the potential
effects on the human proteasome would need to be further investigated. In addition, Nsp6 may
help the virus evade host defenses by limiting the ability of autophagosomes to deliver viral
particles to lysosomes, so limiting its interactions may increase the ability of the host cell to target
its viral invader. One compound in particular, Haloperidol, showed promising results; predicted
docking (via computational molecular docking software) to Nsp6 alone, as well as to Nsp6heteroprotein complexes suggested strong binding, indicating a potential strong interaction that
could impact the viral protein function and thus the viral life cycle.
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INTRODUCTION
The Pandemic
Severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, is the causative agent of the
coronavirus disease 2019 (COVID-19) pandemic1. According to the WHO, since the beginning of
the pandemic in 2019, there have been over 486 million confirmed cases and over 6 million deaths
reported1. Besides the immediate detrimental effects becoming infected with the virus may cause,
it has far-reaching consequences in other areas. Social distancing measures and mandated
lockdowns and closures may lead to a loss of income, which can become a challenge, especially
for those who are already low-income or are living paycheck-to-paycheck2. In addition, avoiding
social gatherings and self-quarantining at home can lead to adverse psychological effects2. In
general, the fear created by the pandemic is associated with higher levels of distress, anxiety, and
depression, potentially exacerbating the salient problem of mental health3. In frontline workers,
the stress of caring for affected patients, the unpredictability of the disease (e.g., negative patient
outcomes despite quality care), and the restrictions from the pandemic, such as use of PPE and
limited patient visiting, correlated with higher psychological distress4. This poses the risk of
lowered performance, or even burnout, among those who are first-in-line to respond to the
pandemic. Thus, because of the widespread impacts of the COVID-19 pandemic, it is important to
search for methods to limit its spread.

Viral Proteins
SARS-CoV-2 contains an RNA genome, which is translated by host machinery. Among the
resulting proteins is a polyprotein that is autoproteolytically cleaved into what are known as
2

nonstructural proteins (Nsps); as their name suggests, rather than being involved in the structural
makeup of the virus, they are involved in processes such as genome replication and transcription5,6.

Despite viral tendency for mutation, some of these nonstructural proteins remain relatively
conserved across human coronaviruses, presumably because of their important functions, pointing
to a possible low tolerance for mutations. For instance, papain-like protease (PLpro),
corresponding to Nsp3, and 3-chymotrypsin-like protease (3CLpro), corresponding to Nsp5, are
highly similar between SARS-CoV and SARS-CoV-2 human coronaviruses7. It is ideal to target
viral components or processes with a low propensity toward mutation as it reduces the likelihood
of the virus becoming resistant to a treatment. In addition, the nonstructural proteins make good
drug targets because they are so vital to the coronavirus life cycle.

ATPases
Vacuolar (H+) ATPases, also known as V-ATPases, are known to play a role in the entry of
enveloped viruses into cells8. While we will not be looking at V-ATPases, but rather P-type
ATPases, it is possible that interactions indicated in P-type ATPases may also be present in VATPases. With this in mind, as well as the numerous other important functions of ATPases, our
study takes a two-pronged approach:
1) Examination of interaction of Nsp3, Nsp5, and Nsp6 with ATPases and evaluation of how
mutations in these proteins observed in viral variants impact these interactions, and
2) Assessment of how certain potentially therapeutic compounds (see Table 1) impact the
predicted interactions of the nonstructural proteins with ATPases

3

If significant interactions are found, this could provide a basis for evaluating the efficacy of these
compounds in living tissue and then as treatments or prevention for SARS-CoV-2.

Cardiac Myosin
While investigating the P-ATPases, the fact that ATPases may be present as part of a larger protein
prompted us to consider looking further. Because of the surprising cardiovascular complications
associated with this respiratory illness, such as myocarditis or thrombotic events, which may
increase disease severity and likelihood of death, we elected to investigate cardiac myosin to search
for interactions and potential treatments, if these interactions do indeed occur9. Cardiac myosin is
essentially the version of myosin found in the heart, which powers the heart’s contractions. The Ptype ATPases we will be investigating in this study are P-type ATPase 13A2 and 13A3 (ATP13A2
and ATP13A3). A preliminary alignment performed using FASTA sequences of Q9H7F0
(ATP13A3) and P12883 (Myosin-7, cardiac) obtained from UniProt revealed an 18.18% identity10,
11, 12

. For ATP13A2 (UniProt Q9NQ11), this number was 19.89%10, 11, 12. Some of this similarity

is presumably due to the ATPase domain of the cardiac myosin. The purpose of investigating this
protein is to pose, and hopefully answer, questions regarding the mechanisms of cardiac
complications seen in COVID-19 patients.

Study Aims
We aim to provide a basis for further research into understanding how SARS-CoV-2 causes the
symptoms it does, as well as collect preliminary data regarding potential therapeutic compounds
for treatment of the disease. The salience and numerous negative impacts of the COVID-19
pandemic, as well as the likelihood that we will eventually coexist with the virus in the same way
4

we do with influenza, makes combating its causative agent of high importance; thus, we aim to
advance knowledge of viral mechanisms to provide scaffolding to produce these solutions in the
future.

5

LITERATURE REVIEW
COVID-19 Nonstructural Proteins
Nsp3
Nsp3 contains papain-like protease, an enzyme that cleaves the N-terminal region of the
polyprotein translated from SARS-CoV-2’s genome to release itself, as well as Nsp27. In addition,
it has been implicated as an antagonist to host immunity, potentially helping the virus to evade the
initial host defenses by deubiquitinating innate immune signaling factors13. Thus, the ability to
limit its protease and/or (predicted) de-ubiquitination activity would be an asset in stopping the
viral life cycle and making the virus more visible to host defenses.

Nsp5
Like Nsp3, Nsp5 performs further protease activity and frees nonstructural proteins 4-167. Because
it is utilized relatively early in the viral life cycle and is responsible for the release of so many
proteins, which in turn proceed to perform their own functions in viral replication, it may be useful
to hinder the protease ability of this protein. Moreover, it is consistent in its cleavage-site
recognition across the coronaviruses, meaning targeting this protein specifically may open an
avenue to treating the Coronaviridae family, as opposed to only SARS-CoV-214.

Nsp6
Nsp6 is one of the SARS-CoV-2 proteins with the highest amount of recurrent mutations15. Many
of these mutations occur as homoplasies, meaning that, despite being commonly observed across
variants, they evolved independently of one another16. This convergence of mutations could point
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to their ability to increase viral viability by improving its ability to survive and replicate in its
hosts, as well as to the overall importance of nonstructural protein 6. Thus, Nsp6 may also be a
valuable drug target in combatting SARS-CoV-2.

Nsp6 has been found to locate to the endoplasmic reticulum (ER) membrane and is associated with
the production of autophagosomes that are more numerous but smaller than those which occur in
response to mTOR inhibition or cellular starvation, which may permit the virus to evade host
defenses by hindering particle transport to lysosomes17. This Nsp6-ER membrane interaction is
facilitated by phenylalanine residues18. Thus, a mutation to a phenylalanine at the proper location
could increase the stability of this interaction and the effectiveness of the viral protein’s ability to
limit the autophagosome response. Supporting this idea, a study found multiple variants with an
L37F mutation in the Nsp6 protein18. Nsp6 has also been shown to interact with ATPases that are
involved in vesicle trafficking19.

ATPases
ATPases are involved in many viral processes, such as endocytosis, exocytosis, and release of viral
RNA into the host cell19. Understanding interactions between viral components and ATPases and
ways to block these interactions thus might lead to effective antiviral treatments.

ATP13A2
Polyamine-transporting ATPase 13A2, which from here on will be referred to as ATP13A2, is a
P-type ATPase expressed in brain tissue10. Some of its functions include polyamine and cation
transport that helps maintain homeostasis and protect against toxicity; it may also be involved in
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the autophagy-lysosome pathway10, 20. Thus, P-type ATPases are highly important to cell survival
because cells rely on polyamines and cations for a wide range of activities as well as require a
well-maintained environment to function properly. In relation to this and what has been previously
discussed regarding Nsp6, the notable subcellular locations of ATP13A2 are the lysosome
membrane and the autophagosome membrane10. Deficiency of or mutations in ATP13A2 are
associated with Parkinson’s disease, and in general, individuals with compromised autophagy
abilities in the brain may encounter neurodegenerative diseases20. With this in mind, we propose
the interaction of nonstructural proteins with P-type ATPases as another potential mechanism in
the “brain fog” and other neurological symptoms seen in some post-COVID patients21. Below is
an image of ATP13A2 to give a reference for the appearance of this protein, whose structure should
be relatively similar to that of ATP13A322.

Figure 1: ATP13A2 P5B-ATPase structure. From “Structural basis of polyamine transport by
human ATP13A2 (PARK9)” by Sim, S. I. et al., 2021, Molecular Cell, 81(22), pp. 4635-4649
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ATP13A3
Polyamine-transporting ATPase 13A3 (ATP13A3) is another P-type ATPase that is similar to
ATP13A2 in its reported ability to transport polyamines and cations10. While not as well
characterized as ATP13A2, it appears to be broadly expressed across tissues and present in
endosomes (mainly recycling)10. Mutations resulting in loss of function of ATP13A3 are
associated with pulmonary arterial hypertension (PAH)23. In COVID-19, pulmonary hypertension
is a potential complication whose causes are somewhat unclear24. If interactions are observed
between ATP13A3 and coronavirus proteins, it is possible that the interaction could be an
underlying mechanism for the development of pulmonary hypertension in COVID and postCOVID patients.

Cardiac Myosin
SARS-CoV-2 is associated with cardiac complications, such as acute myocardial injury; in
addition, potential long-term implications in individuals infected with SARS-CoV-2, which
remain to be seen, are indicated by 12-year follow-up history of individuals infected with the
similar virus, SARS-CoV, during the height of its spread25. Individuals who were infected with
SARS-CoV and who recovered appeared with increased incidence of dysregulation of lipid
metabolism compared to uninfected individuals, presenting with higher serum concentrations of
free fatty acids and other markers, suggestive of chronic cardiovascular damage25. The mechanism
of cardiac complications in SARS-CoV and SARS-CoV-2 is unknown but proposed to be via
ACE2 signaling pathways due to viral reliance on the receptor for cell entry, or due to a cytokine
storm (inflammatory response)25. Healthcare providers should thus monitor patients who are
infected with SARS-CoV-2 for similar complications.
9

Another potential mechanism for cardiac complications is via molecular mimicry. Certain viruses,
such as those belonging to coxsackievirus group B (CVB) have been implicated as potential
triggers of myocarditis, as evidenced by higher levels of antibodies in the serum of affected
individuals, when compared with unaffected individuals26. These patients were also found to
possess higher levels of autoantibodies to certain cardiac proteins, and these autoantibodies could
be removed from the serum using purified CVB particles, indicating the possibility that the cardiac
proteins and viral components shared similar epitopes that could both be recognized by crossreacting antibodies26. CVB3-infected mice with resulting chronic myocarditis were found to
possess anti-cardiac myosin antibodies, suggesting an immune response could have been invoked
and subsequently led to cardiac complications26. If SARS-CoV-2 possesses similar epitopes to
cardiac myosin, then cardiac manifestations of COVID-19 could be explained in this manner.
Alternatively, if the viral components contain regions that produce energetically favorable
interactions with cardiac myosin, cardiac complications could result from either direct disruption
of function or via immune targeting to the viral component that inadvertently involves the cardiac
myosin as well (these mechanisms could be hypothesized for other cardiac proteins, as well).

Therapeutic Compounds
Currently, there are numerous treatments in use for COVID-19, as well as other compounds that
have been identified as potential interactors with viral components. For the purposes of this study,
we have selected a combination of currently in-use as well as potential compounds (identified
computationally by previous studies done by other researchers), a list of which is shown in Table
1. The chemical structures of these compounds are included in Appendix A.
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Table 1. Compounds for investigation
Compound Name

SARS-CoV-2
Protein (what
protein[s] will it
be docked with?)

Famotidine

All

Function

a.
b.
c.

Molnupiravir

All

a.

Folic acid

Nsp3

a.

Apicidin

Nsp5

a.
b.

Valproic acid

Nsp5

a.
b.
c.

Bafilomycin A1

Nsp6

a.
b.

Haloperidol

Nsp6

a.
b.
c.

Histamine-2 receptor antagonist; used
to inhibit production of gastric acid27
Potential 3CLpro inhibitor7
Preliminary studies show its
association with reduced risk of death,
intubation27
Nucleoside analog that acts a substrate
for viral RNA-dependent RNA
polymerase and results in lethal
transition mutations in the viral RNA28
May block proteolytic activity of
Nsp3 and inhibit viral replication30
Histone deacetylase class I (HDAC1)
inhibitor31
Potential treatment for heart failure,
cardiac hypertrophy32
HDAC2 inhibitor31
Approved antiepileptic drug33
May influence rate of protein
synthesis or degradation of HDAC2
via the ubiquitin proteasome
pathway33
ATPase inhibitor8
Inhibits acidification of lysosomes by
interacting with vacuolar H+transporting ATPases in membranes
of lysosomes34
Sigma 1 & 2 receptor modulator31
Psychotropic drug35
Induces Sigma 1 receptor protein
expression (this receptor is often
found in the ER membrane, where
Nsp6 localizes)35

Currently in use
for COVID-19
treatment, or
identified for
potential use?
Potential

Emergency Use
Authorization
granted by FDA29
Potential
Potential

Potential

Potential

Potential

Note: We chose to dock Molnupiravir with all three nonstructural proteins despite its mechanism
already being known to determine if it has any other potential interactions or effects.
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Famotidine
Famotidine is a drug that can suppress gastric acid production by blocking histamine-2 receptors;
thus, it is useful for treating conditions caused by an excess of gastric acid27. It has also been
observed to inhibit replication of HIV in vitro27. This molecule is predicted to be able to bind and
inhibit 3CLpro, a component of Nsp57. Its ability to inhibit HIV replication combined with its
predicted binding to Nsp5 are promising, because they suggest that it might be able to also limit
SARS-CoV-2 through similar mechanisms. Preliminary studies regarding patients who were given
famotidine in the early stages of their infection showed reduced risk of death and intubation in
those who received famotidine when compared to those who did not27.

Molnupiravir
Molnupiravir is an orally bioavailable ribonucleoside analog that acts as a substrate for RNAdependent RNA polymerases and causes lethal transition mutations in the viral genome28. This
antiviral is emerging as an effective and safe short-term treatment for COVID-19 and appears to
be effective in cases that do not respond to remdesivir28. However, in the long term, it may have
genotoxic effects due to its mechanism of action, though findings on this are mixed28. It is also
somewhat time-dependent, in that it is most effective when administered beginning early on in
infection28. Nevertheless, Molnupiravir appears to be a promising treatment for COVID-19. Thus,
it has been granted emergency use authorization by the FDA while it moves through the process
of gaining full approval29.
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Folic acid
Folic acid, also known as Vitamin B9, is a dietary supplement that is important for many cellular
processes as well as fetal central nervous system development. A study performed by Jung, Gund,
& Narayan (2020) identified folic acid as the number one candidate, among 682 FDA-approved
compounds and 10 reference compounds, for inhibition of SARS-CoV-2 replication and thus
COVID-19 treatment30. Folic acid may be able to inhibit SARS-CoV-2 replication via the
inhibition of furin, which would in turn prevent it from binding the viral spike protein and thus
stop viral entry into the host cell30. It also might block the proteolytic activity of Nsp330.

Apicidin
Apicidin is a cyclic peptide which acts as an HDAC inhibitor31, 32. Some studies have found that
suppression of HDAC activity prevents myocardial hypertrophy, the proposed mechanism being
through suppression of genes that would trigger this condition32. It is proposed to interact with
Nsp531. If this is the case, and if it does indeed have a protective effect against hypertrophy, it
could be useful in treating both the virus itself as well as the cardiac complications that may
accompany it.

Valproic acid
Valproic acid is an HDAC inhibitor that may interact with Nsp531. It is currently in use as an
antiepileptic33. If it can both interact with Nsp5 and act as an HDAC inhibitor in COVID patients,
its potential benefits could be similar to those of Apicidin, mentioned above.
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Bafilomycin A1
Bafilomycin A1 is an antibiotic which inhibits vacuolar-type (H+) ATPases, thus inhibiting
lysosome acidification8,

34

. Because V-ATPases are involved in the cellular entry of some

enveloped viruses, it may be useful to have a way to limit their activity in patients suffering from
COVID-198. Although we are not studying V-ATPases, but rather P-ATPases, it is possible that
an interaction with one ATPase could translate into an interaction with another type of ATPase.

Haloperidol
Haloperidol is a Sigma 1 and 2 receptor modulator31. It functions as an antipsychotic by inhibiting
dopamine D2 and histamine H1 receptors35. Because Sigma receptors are involved in the ER stress
response, drugs that target these may limit viral replication by affecting this response35. Nsp6 is
thought to interact with the Sigma receptors involved in the ER stress response, so targeting Nsp6
and/or the Sigma receptor could be a unique way to hinder the ability of the coronavirus to
propagate35.
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METHODS
This study was conducted using computational software to model protein structures, proteinprotein interactions, and small-molecule molecular docking. The nonstructural protein amino acid
sequences were pulled from the Zhang Lab website35, and the ATP13A2, ATP13A3, and Cardiac
Myosin amino acid structures were obtained from the UniProt website10. All compounds listed in
Table 1 (used for small-molecule molecular docking using computational methods) were
downloaded from PubChem37 as SDF files and converted to PDBQT files using OpenBabel38.
Protein-protein interactions were predicted using ClusPro39, 40, 41, 42. Because we were not sure
where the potential interactions would be for the proteins tested, we modeled amino acid
interactions using the Balanced tool; however, to get a more specific idea of binding affinities and
interactions within the cell, we elected to use the Van der Wals + Electrostatics (VdW + Elec
option) and averaged the top six results, which are model scores that represent relative energy units
for comparison purposes (but which are unitless themselves), the results of which are summarized
in Table 3. To see interacting amino acids, the resulting ClusPro Balanced File labeled “0” (chosen
because it has the most interacting partners) was opened in PyMOL, and amino acids within 5
angstroms of the interacting partner on each protein were selected and color-coded, because they
would be most likely to be involved in the protein-protein interaction42. A subset of interactions
was chosen to pursue for further molecular docking using computational methods based on a
combination of energetic favorability and representation of all proteins discussed earlier;
molecular docking using computational methods was then performed using PyRx’s AutoDock
Vina function to predict favorability and location of protein-molecule interactions44. Interactions
of nonstructural proteins with potential therapeutic molecules were also pursued in isolation of
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other proteins because we are unsure what interactions do or do not occur in vivo, or in what order
they might occur. Blind molecular docking using computational methods was pursued except in
instances where there was not enough computing power to handle the size of the molecular docking
request, in which case the Grid Box size was slowly reduced, attempting to keep as much of the
protein(s) in as possible, until the program would run properly. Additionally, because cardiac
myosin was included as a protein of interest in this study, we also elected to examine the interaction
of our ATPases with F-actin (F-actin PDB ID: 5ONV). Table 2 lists all interactions performed.
The Nsp3, Nsp5, and Nsp6 protein structures were obtained from the Zhang lab, and the PDB IDs
used for ATP13A2 and Cardiac Myosin were7N72 and 4P7H, respectively; for ATP13A3, the
alpha fold structure prediction PDB from UniProt Q9H7F0 was used.

16

Table 2. List of interactions performed
Protein 1
Nsp3

Protein 2
ATP13A2

Nsp3

Cardiac Myosin

Nsp3
Nsp5

Cardiac Myosin

Nsp5
Nsp6

ATP13A3

Nsp6
ATP13A2
Nsp3
Nsp3
Nsp5
Nsp3
Nsp5
Nsp5
Nsp6
Nsp6
ATP13A3

F-actin
Nsp6
Nsp5
Nsp6
ATP13A3
ATP13A3
ATP13A2
Cardiac myosin
ATP13A2
F-actin
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Compounds
Folic Acid, Famotidine,
Molnupiravir
Folic Acid, Famotidine,
Molnupiravir
Folic Acid, Famotidine,
Molnupiravir
Valproic Acid, Apicidin,
Famotidine, Molnupiravir
Valproic Acid, Apicidin,
Famotidine, Molnupiravir
Bafilomycin A1, Haloperidol,
Famotidine, Molnupiravir
Bafilomycin A1, Haloperidol,
Famotidine, Molnupiravir

RESULTS
Initial modeling of protein-protein interactions with ClusPro and PyMOL revealed the average
model scores seen in Table 3, ranked from most to least favorable based on average VdW + Elec
model scores from ClusPro. After realizing that the Cardiac Myosin protein model had a GFP tag,
we removed GFP and recalculated and re-docked interactions involving GFP.
Table 3. ClusPro model scores for protein-protein interactions
Interaction

ClusPro Model Scores

ATP13A2 vs Nsp3

-734.3

Nsp3 vs Nsp6

-543.1

ATP13A3 vs Nsp3

-497.8

Cardiac Myosin vs Nsp3

-399.8

ATP13A2 vs F-actin

-342.5

Cardiac Myosin (Without GFP Tag) vs Nsp3

-332.5

ATP13A3 vs F-actin

-302.8

ATP13A3 vs Nsp6

-275.1

Cardiac Myosin vs Nsp6

-244.4

Cardiac Myosin vs Nsp5

-231

Nsp3 vs Nsp5

-222.7

ATP13A2 vs Nsp5

-211.6

Cardiac Myosin (Without GFP Tag) vs Nsp6

-209

ATP13A3 vs Nsp5

-208.1

Cardiac Myosin (Without GFP Tag) vs Nsp5

-201.4

ATP13A2 vs Nsp6

-195.4

Nsp5 vs Nsp6

-176.1
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By far, the most favorable interaction appears to be ATP13A3 and Nsp3, followed by Nsp3 and
Nsp6 and then ATP13A3 and Nsp3. In order to balance inspection of most favorable interactions
and inclusion of all chosen proteins, we selected ATP13A2 vs Nsp3, Cardiac Myosin vs Nsp3,
ATP13A2 vs F-actin, ATP13A3 vs Nsp6, and Cardiac Myosin vs Nsp5 for further analysis. The
findings of each interaction are listed individually below as well as summarized in Table 4.

ATP13A2 vs Nsp3
Figure 1 shows the PyMOL-generated image of the balanced protein-protein interaction between
ATP13A2 (green) and Nsp3 (blue) predicted by ClusPro. When the VdW +Elec Cluspro model
scores for the top 6 predicted interactions, in terms of number of interacting partners, were
averaged, the ClusPro model score for this pairing was highly negative at -734.3. Figure 2 shows
a color-coded version of the same interaction seen in Figure 1 (generated using the same
programs); the pink areas represent amino acid residues on Nsp3 which are within 5 angstroms of
ATP13A2, and the green, the reverse. On the left is the surface model, and on the right, the cartoon
model of this interaction. This ATP13A2-Nsp3 complex was then input into PyRx AutoDock Vina
for computational small molecule docking of folic acid, Famotidine, and Molnupiravir, the results
of which are discussed below. A labeled version of ATP13A2 can be found in Appendix C.

As seen in Figure 3, the most energetically favorable ATP13A2-Nsp3 complex (pink and white)
vs folic acid (blue) docking predicted by PyRx AutoDock Vina had an estimated binding energy
of -5.7 kcal/mol. In Figure 4, the most energetically favorable ATP13A2-Nsp3 complex (pink and
white) vs famotidine (blue) interaction predicted by PyRx AutoDock Vina was -6.6 kcal/mol. In
Figure 5, the most energetically favorable ATP13A2-Nsp3 complex (pink and white) vs
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Molnupiravir docking predicted by PyRx AutoDock Vina was the highest of the three investigated
compounds at -8.2 kcal/mol. In all three of these figures, pink represents residues on the proteinprotein complex which are within 5 angstroms of their docked molecules in one or more of the top
9 most energetically favorable results generated from PyRx AutoDock Vina.

Figure 1. ATP13A2 (green) and Nsp3 (blue) interaction generated by PyMOL based on
ClusPro results

Figure 2: ATP13A2 (green) and Nsp3 (pink) interaction
Left: Surface model generated by PyMOL based on ClusPro results
Right: Cartoon model generated by PyMOL based on ClusPro results
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Folic Acid

Figure 3: ATP13A2-Nsp3 complex (pink and white) vs folic acid (blue) most energetically
favorable result generated by PyRx AutoDock Vina (predicted molecular docking energy: -5.7
kcal/mol); ATP13A2-Nsp3 complex generated via ClusPro and image generated by PyMOL.
Different regions of pink indicate the top 9 most energetically favorable docking locations
predicted by PyRx AutoDock Vina.
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Famotidine

Figure 4: ATP13A2-Nsp3 complex (pink and white) vs famotidine (blue) most energetically
favorable result generated by PyRx AutoDock Vina (predicted molecular docking energy: -6.6
kcal/mol); ATP13A2-Nsp3 complex generated via ClusPro and image generated by PyMOL.
Different regions of pink indicate the top 9 most energetically favorable docking locations
predicted by PyRx AutoDock Vina.
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Molnupiravir

Figure 5: ATP13A2-Nsp3 complex (pink and white) vs Molnupiravir (blue) most energetically
favorable result generated by PyRx AutoDock Vina (predicted molecular docking energy: -8.2
kcal/mol); ATP13A2-Nsp3 complex generated via ClusPro and images generated by PyMOL.
Different regions of pink indicate the top 9 most energetically favorable docking locations
predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina

Cardiac Myosin vs Nsp3 (Includes GFP Tag)
Figure 6 shows the PyMOL-generated image of the balanced protein-protein interaction between
cardiac myosin (green) and Nsp3 (blue) predicted by ClusPro. When the VdW +Elec Cluspro
model scores for the top 6 predicted interactions, in terms of number of interacting partners, were
averaged, the model score was -399.8. Figure 7 shows a color-coded version of the same
interaction seen in Figure 6 (generated using the same programs); the pink areas represent amino
acid residues on Nsp3 which are within 5 angstroms of cardiac myosin, and the green, the reverse.
On the left is the surface model, and on the right the cartoon model, of this interaction. This Cardiac
Myosin-Nsp3 complex was then input into PyRx AutoDock Vina for computational small
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molecule docking of Folic Acid, Famotidine, and Molnupiravir, the results of which are discussed
below.

As seen in Figure 8, the most energetically favorable Cardiac Myosin-Nsp3 complex (pink and
white) vs Folic Acid (blue) docking predicted by PyRx AutoDock Vina had an estimated binding
energy of -4.6 kcal/mol. In Figure 9, the most energetically favorable Cardiac Myosin-Nsp3
complex (pink and white) vs Famotidine (blue) interaction predicted by PyRx AutoDock Vina was
-6.2 kcal/mol. In Figure 10, the second most energetically favorable Cardiac Myosin-Nsp3
complex (pink and white) vs Molnupiravir (blue) docking predicted by PyRx AutoDock Vina was
the highest of the three investigated compounds at -7.1 kcal/mol. The second result was chosen
due to Molnupiravir docking in the Nsp3, rather than the Cardiac Myosin, region of the protein
complex; the most energetically favorable docking of this interaction was only slightly better at 7.2 kcal/mol. In all four of these figures, pink represents residues on the protein-protein complex
which are within 5 angstroms of their docked molecules in one or more of the top 9 most
energetically favorable results generated from PyRx AutoDock Vina.
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Figure 6: Cardiac myosin (green) and Nsp3 (blue) interaction generated by PyMOL based on
ClusPro results (Note: GFP is involved in the interaction seen here)

Figure 7: Cardiac myosin (green) and Nsp3 (pink) interacting amino acids (Note: the betabarrel structure seen interacting belongs to GFP)
Left: Surface model generated by PyMOL based on ClusPro results
Right: Cartoon model generated by PyMOL based on ClusPro results
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Folic Acid

Figure 8: Cardiac Myosin-Nsp3 complex (pink and white) vs folic acid (blue) most
energetically favorable result generated by PyRx AutoDock Vina (predicted molecular
docking energy: -4.6 kcal/mol); cardiac myosin-Nsp3 complex predicted via ClusPro and
images generated by PyMOL. Different regions of pink indicate the top 9 most energetically
favorable docking locations predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina

Famotidine

Figure 9: Cardiac Myosin-Nsp3 complex (pink and white) vs Famotidine (blue) most
energetically favorable result generated by PyRx AutoDock Vina (predicted molecular
docking energy: -6.2 kcal/mol); cardiac myosin-Nsp3 complex predicted via ClusPro and
images generated by PyMOL. Different regions of pink indicate the top 9 most energetically
favorable docking locations predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina
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Molnupiravir

Figure 10: Cardiac Myosin-Nsp3 complex (pink and white) vs Molnupiravir (blue) second
most energetically favorable result (chosen because of its docking to Nsp3 rather than cardiac
myosin) generated by PyRx AutoDock Vina (predicted molecular docking energy: -7.1
kcal/mol; predicted most favorable molecular docking energy: -7.2); cardiac myosin-Nsp3
complex generated via ClusPro and images generated by PyMOL. Different regions of pink
indicate the top 9 most energetically favorable docking locations predicted by PyRx AutoDock
Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the second most energetically favorable
interaction predicted by PyRx AutoDock Vina

ATP13A2 vs F-actin
Figures 11 and 12 show the PyMOL images of the ClusPro-generated prediction of the interaction
between ATP13A2 and F-actin. The images shown are of the “Balanced” ClusPro result generated
with the most interacting partners, and when the VdW + Elec Cluspro model scores for the top 6
predicted interactions, in terms of number of interacting partners, were averaged, the resulting
average ClusPro model score was -342.5. Figure 12 shows a color-coded version of Figure 11, in
which the amino acids on ATP13A2 within 5 angstroms of F-actin are represented by green and
the residues on F-actin within 5 angstroms of ATP13A2 are represented by pink (the left shows
the surface model of this, and the right shows the cartoon model).
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Figure 11: ATP13A2 (green) vs F-actin (blue) interaction generated by PyMOL based on
ClusPro results

Figure 12: ATP13A2 (green) and F-actin (pink) interacting amino acids
Left: Surface model generated by PyMOL based on ClusPro results
Right: Cartoon model generated by PyMOL based on ClusPro results
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ATP13A3 vs Nsp6
Figure 13 shows the PyMOL-generated image of the balanced protein-protein interaction between
ATP13A3 (green) and Nsp6 (blue) predicted by ClusPro. When the VdW +Elec Cluspro model
scores for the top 6 predicted interactions, in terms of number of interacting partners, were
averaged, the result was -275.1. Figure 14 shows a color-coded version of the same interaction
seen in Figure 13 (generated using the same programs); the pink areas represent amino acid
residues on ATP13A3 which are within 5 angstroms of Nsp6, and the green the reverse. On the
left is the surface model, and on the right the cartoon model, of this interaction. This ATP13A3Nsp6 complex was then input into PyRx AutoDock Vina for computational small molecule
docking of Bafilomycin A1, Haloperidol, Famotidine, and Molnupiravir, the results of which are
discussed below. A labeled version of ATP13A3 can be found in Appendix C.

As seen in Figure 15, the most energetically favorable ATP13A3-Nsp6 complex (pink and white)
vs Bafilomycin A1 (blue) docking predicted by PyRx AutoDock Vina had an estimated binding
energy of -8.1 kcal/mol. In Figure 16, the most energetically favorable ATP13A3-Nsp6 complex
(pink and white) vs Haloperidol (blue) interaction predicted by PyRx AutoDock Vina was -9.0
kcal/mol. In Figure 17, the most energetically favorable ATP13A3-Nsp6 complex (pink and white)
vs Famotidine (blue) docking predicted by PyRx AutoDock Vina was -6.0 kcal/mol. In Figure 18,
the most energetically favorable ATP13A3-Nsp6 complex (pink and white) vs Molnupiravir (blue)
docking predicted by PyRx AutoDock Vina was -7.6 kcal/mol. In all four of these figures, pink
represents residues on the protein-protein complex which are within 5 angstroms of their docked
molecules in one or more of the top 9 most energetically favorable results generated from PyRx
AutoDock Vina.
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Figure 13: ATP13A3 (green) vs Nsp6 (blue) interaction generated by PyMOL based on
ClusPro results

Figure 14: ATP13A3 (pink) and Nsp6 (green) interaction
Left: Surface model generated by PyMOL based on ClusPro results
Right: Cartoon model generated by PyMOL based on ClusPro results
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Bafilomycin A1

Figure 15: ATPa3-Nsp6 complex (pink and white) vs Bafilomycin A1 (blue) most
energetically favorable result predicted by PyRx AutoDock Vina (predicted molecular docking
energy: -8.1 kcal/mol); ATP13A3-Nsp6 complex generated via ClusPro and images generated
by PyMOL. Different regions of pink indicate the top 9 most energetically favorable docking
locations predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina

Haloperidol

Figure 16: ATP13A3-Nsp6 complex (pink and white) vs Haloperidol (blue) most energetically
favorable result predicted by PyRx AutoDock Vina (predicted molecular docking energy: -9.0
kcal/mol); ATP13A3-Nsp6 complex generated via ClusPro and images generated by PyMOL.
Different regions of pink indicate the top 9 most energetically favorable docking locations
predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina
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Famotidine

Figure 17: ATP13A3-Nsp6 complex (pink and white) vs Famotidine (blue) most energetically
favorable result predicted by PyRx AutoDock Vina (predicted molecular docking energy: -6.0
kcal/mol); ATP13A3-Nsp6 complex generated via ClusPro and images generated by PyMOL.
Different regions of pink indicate the top 9 most energetically favorable docking locations
predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina

Molnupiravir

Figure 18: ATP13A3-Nsp6 complex (pink and white) vs Molnupiravir (blue) most
energetically favorable result predicted by PyRx AutoDock Vina (predicted molecular docking
energy: -7.6 kcal/mol); ATP13A3-Nsp6 complex generated via ClusPro and images generated
by PyMOL. Different regions of pink indicate the top 9 most energetically favorable docking
locations predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina
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Cardiac Myosin vs Nsp5
Figure 19 shows the PyMOL-generated image of the balanced protein-protein interaction between
Cardiac Myosin (green) and Nsp5 (blue) predicted by ClusPro. When the VdW +Elec Cluspro
model scores for the top 6 predicted interactions, in terms of number of interacting partners, were
averaged, the resulting average ClusPro model score was -231. Figure 20 shows a color-coded
version of the same interaction seen in Figure 19 (generated using the same programs); the pink
areas represent amino acid residues on Cardiac Myosin which are within 5 angstroms of Nsp5, and
the green the reverse. On the left is the surface model, and on the right the cartoon model, of this
interaction. This Cardiac Myosin-Nsp5 complex was then input into PyRx AutoDock Vina for
computational small molecule docking of Valproic Acid, Apicidin, Famotidine, and Molnupiravir,
the results of which are discussed below.

As seen in Figure 21, the most energetically favorable Cardiac Myosin-Nsp5 complex (pink and
white) vs valproic acid (blue) docking predicted by PyRx AutoDock Vina had an estimated binding
energy of -5.1 kcal/mol. In Figure 22, the most energetically favorable Cardiac Myosin-Nsp5
complex (pink and white) vs Apicidin (green) interaction predicted by PyRx AutoDock Vina was
-7.3 kcal/mol. In Figure 23, the most energetically favorable Cardiac Myosin-Nsp5 complex (pink
and white) vs Famotidine (blue) docking predicted by PyRx AutoDock Vina was -5.6 kcal/mol. In
Figure 24, the most energetically favorable Cardiac Myosin-Nsp5 complex (pink and white) vs
Molnupiravir (blue) docking predicted by PyRx AutoDock Vina was -7.8 kcal/mol. In all four of
these figures, pink represents residues on the protein-protein complex which are within 5
angstroms of their docked molecules in one or more of the top 9 most energetically favorable
results generated from PyRx AutoDock Vina.
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Figure 19: Cardiac Myosin (green) vs Nsp5 (blue) interaction generated by PyMOL based on
ClusPro results (Note: This figure involves GFP in the interaction)

Figure 20: Cardiac myosin (pink) and nsp5 (green) interacting amino acids (Note: This figure
involves GFP in the interaction)
Left: Surface model generated by PyMOL based on ClusPro results
Right: Cartoon model generated by PyMOL based on ClusPro results
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Valproic Acid

Figure 21: Cardiac Myosin-Nsp5 complex (pink and white) vs valproic acid (blue) most
energetically favorable result predicted by PyRx AutoDock Vina (predicted molecular docking
energy: -5.1 kcal/mol); cardiac myosin-Nsp5 complex generated via ClusPro and images
generated by PyMOL. Different regions of pink indicate the top 9 most energetically favorable
docking locations predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina

Apicidin

Figure 22: Cardiac Myosin-Nsp5 complex (pink and white) vs Apicidin (green) most
energetically favorable result predicted by PyRx AutoDock Vina (predicted molecular docking
energy: -7.3 kcal/mol); cardiac myosin-Nsp5 complex generated via ClusPro and images
generated by PyMOL. Different regions of pink indicate the top 9 most energetically favorable
docking locations predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina
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Famotidine

Figure 23: Cardiac Myosin-Nsp5 complex (pink and white) vs Famotidine (blue) most
energetically favorable result predicted by PyRx AutoDock Vina (predicted molecular docking
energy: -5.6 kcal/mol); cardiac myosin-Nsp5 complex generated via ClusPro and images
generated by PyMOL. Different regions of pink indicate the top 9 most energetically favorable
docking locations predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina

Molnupiravir

Figure 24: Cardiac Myosin-Nsp5 complex (pink and white) vs Molnupiravir (blue) most
energetically favorable result predicted by PyRx AutoDock Vina (predicted molecular docking
energy: -7.8 kcal/mol); cardiac myosin-Nsp5 complex generated via ClusPro and images
generated by PyMOL. Different regions of pink indicate the top 9 most energetically favorable
docking locations predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina
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Nsp3 Only
Folic Acid
Figure 25 shows the PyMOL-generated images of the most energetically favorable Nsp3 (pink and
white) vs folic acid (blue) small molecule docking prediction made by PyRx AutoDock Vina; the
estimated binding energy was -4.8 kcal/mol. Pink represents regions on the protein which are
within 5 angstroms of folic acid in one or more of the top 9 most energetically favorable results
generated from PyRx AutoDock Vina.

Figure 25: Nsp3 (pink and white) vs folic acid (green) most energetically favorable result
generated by PyRx AutoDock Vina (predicted molecular docking energy: -4.8 kcal/mol);
images generated by PyMOL. Different regions of pink indicate the top 9 most energetically
favorable docking locations predicted by PyRx AutoDock Vina.
Left: Whole-complex cartoon modeling
Right: Cartoon modeling closeup of the most energetically favorable interaction
predicted by PyRx AutoDock Vina

Famotidine
Figure 26 shows the PyMOL-generated image of the most energetically favorable Nsp3 (pink and
white) vs famotidine (green) small molecule docking prediction made by PyRx AutoDock Vina;
the estimated binding energy was -6.3 kcal/mol. Pink represents residues on the protein which are
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within 5 angstroms of Famotidine in one or more of the top 9 most energetically favorable results
generated from PyRx AutoDock Vina.

Figure 26: Nsp3 (pink and white) vs Famotidine (green) most energetically favorable result
generated by PyRx AutoDock Vina (predicted molecular docking energy: -6.3 kcal/mol);
image generated by PyMOL. Different regions of pink indicate the top 9 most energetically
favorable docking locations predicted by PyRx AutoDock Vina.

Molnupiravir
Figure 27 shows the PyMOL-generated image of the most energetically favorable Nsp3 (pink and
white) vs molnupiravir (green) small molecule docking prediction made by PyRx AutoDock Vina;
the estimated binding energy was -7.0 kcal/mol. Pink represents residues on the protein which are
within 5 angstroms of Molnupiravir in one or more of the top 9 most energetically favorable results
generated from PyRx AutoDock Vina.
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Figure 27: Nsp3 (pink and white) vs Molnupiravir (green) most energetically favorable result
generated by PyRx AutoDock Vina (predicted molecular docking energy: -7.0 kcal/mol);
image generated by PyMOL. Different regions of pink indicate the top 9 most energetically
favorable docking locations predicted by PyRx AutoDock Vina.

Nsp5 Only
Valproic Acid
Figure 28 shows the PyMOL-generated images of the most energetically favorable Nsp5 (pink and
white) vs Molnupiravir (blue) small molecule docking prediction made by PyRx AutoDock Vina;
the estimated binding energy was -4.2 kcal/mol. Pink represents residues on the protein which are
within 5 angstroms of Valproic Acid in one or more of the top 9 most energetically favorable
results generated from PyRx AutoDock Vina.
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Figure 28: Nsp5 (pink and white) vs Valproic Acid (blue) most energetically favorable result
generated by PyRx AutoDock Vina (predicted molecular docking energy: -4.2 kcal/mol);
images generated by PyMOL. Different regions of pink indicate the top 9 most energetically
favorable docking locations predicted by PyRx AutoDock Vina.
Left: Surface model generated by PyMOL based on predictions from
PyRx AutoDock Vina
Right: Cartoon model generated by PyMOL based on predictions from PyRx
AutoDock Vina
Apicidin
Figure 29 shows the PyMOL-generated images of the most energetically favorable Nsp5 vs
apicidin (green) small molecule docking prediction made by PyRx AutoDock Vina; the estimated
binding energy was -6.3 kcal/mol. The top left image shows the general surface model of the most
energetically favorable computationally predicted docking of Apicidin (green) to Nsp5 (blue). The
top right image shows a color-coded version of this image; purple represents residues on the
protein which are within 5 angstroms of Apicidin in one or more of the top 9 most energetically
favorable results generated from PyRx AutoDock Vina. The bottom left image shows the cartoon
model version of these interactions.
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Figure 29: Nsp5 vs Apicidin most energetically favorable result generated by PyRx AutoDock
Vina (predicted molecular docking energy: -6.3 kcal/mol); images generated by PyMOL.
Different regions of purple indicate the top 9 most energetically favorable docking locations
predicted by PyRx AutoDock Vina.
Top Left: Surface model created by PyMOL based on predictions from PyRx
AutoDock Vina (Nsp5: blue; Apicidin: green)
Top Right: Surface model created by PyMOL of based on predictions from
PyRx AutoDock Vina showing amino acids (purple) within 5 angstroms of
Apicidin (green)
Bottom Left: Cartoon model model created by PyMOL of based on predictions
generated by PyRx AutoDock Vina showing amino acids (purple) within 5
angstroms of Apicidin (green)

Famotidine
Figure 30 shows the PyMOL-generated images of the most energetically favorable Nsp5 (purple
and white) vs famotidine (green) small molecule docking prediction made by PyRx AutoDock
Vina; the estimated binding energy was -5.4 kcal/mol. Purple represents residues on the protein
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which are within 5 angstroms of Famotidine in one or more of the top 9 most energetically
favorable results generated from PyRx AutoDock Vina.

Figure 30: Nsp5 vs Famotidine most energetically favorable result generated by PyRx
AutoDock Vina (predicted molecular docking energy: -5.4 kcal/mol); images generated by
PyMOL. Different regions of purple indicate the top 9 most energetically favorable docking
locations predicted by PyRx AutoDock Vina.
Left: Surface model created by PyMOL based on predictions from PyRx
AutoDock Vina Vina showing amino acids (purple) within 5 angstroms of
Famotidine (green)
Right: Cartoon model created by PyMOL of based on predictions from PyRx
AutoDock Vina showing amino acids (purple) within 5 angstroms of
Famotidine (green)

Molnupiravir
Figure 31 shows the PyMOL-generated images of the most energetically favorable Nsp5 vs
molnupiravir (green) small molecule docking prediction made by PyRx AutoDock Vina; the
estimated binding energy was -6.7 kcal/mol. The top left image shows the general surface model
of the most energetically favorable computationally predicted docking of Molnupiravir (green) to
Nsp5 (blue). The top right image shows a color-coded version of this image; purple represents
residues on the protein which are within 5 angstroms of Molnupiravir in one or more of the top 9
most energetically favorable results generated from PyRx AutoDock Vina. The bottom left image
shows the cartoon model version of these interactions.
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Figure 31: Nsp5 vs Molnupiravir most energetically favorable result generated by PyRx
AutoDock Vina (predicted molecular docking energy: -6.7 kcal/mol); images generated by
PyMOL. Different regions of purple indicate the top 9 most energetically favorable docking
locations predicted by PyRx AutoDock Vina.
Top Left: Surface model created by PyMOL based on predictions from PyRx
AutoDock Vina (Nsp5: blue; Molnupiravir: green)
Top Right: Surface model created by PyMOL of based on predictions from
PyRx AutoDock Vina showing amino acids (purple) within 5 angstroms of
Molnupiravir (green)
Bottom Left: Cartoon model model created by PyMOL of based on predictions
generated by PyRx AutoDock Vina showing amino acids (purple) within 5
angstroms of Molnupiravir (green)

Nsp6 Only
Bafilomycin A1
Figure 32 shows the PyMOL-generated images of the most energetically favorable Nsp6 vs
Bafilomycin A1 (green) small molecule docking prediction made by PyRx AutoDock Vina; the
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estimated binding energy was -7.4 kcal/mol. The top left image shows the general surface model
of the most energetically favorable computationally predicted docking of Bafilomycin A1 (green)
to Nsp6 (blue). The top right image shows a color-coded version of this image; pink represents
residues on the protein which are within 5 angstroms of Bafilomycin A1 in one or more of the top
9 most energetically favorable results generated from PyRx AutoDock Vina. The bottom left
image shows the cartoon model version of these interactions.

Figure 32. Nsp6 vs Bafilomycin A1 most energetically favorable result generated by PyRx
AutoDock Vina (predicted molecular docking energy: -7.4 kcal/mol); images generated by
PyMOL. Different regions of pink indicate the top 9 most energetically favorable docking
locations predicted by PyRx AutoDock Vina.
Top Left: Surface model created by PyMOL based on predictions from PyRx
AutoDock Vina (Nsp6: blue; Bafilomycin A1: green)
Top Right: Surface model created by PyMOL of based on predictions from
PyRx AutoDock Vina showing amino acids (pink) within 5 angstroms of
Bafilomycin A1 (green)
Bottom Left: Cartoon model model created by PyMOL of based on predictions
generated by PyRx AutoDock Vina showing amino acids (pink) within 5
angstroms of Bafilomycin A1 (green)
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Haloperidol
Figure 33 shows the PyMOL-generated images of the most energetically favorable Nsp6 vs
Haloperidol (green) small molecule docking prediction made by PyRx AutoDock Vina; the
estimated binding energy was -7.3 kcal/mol. The top left image shows the general surface model
of the most energetically favorable computationally predicted docking of Haloperidol (green) to
Nsp6 (blue). The top right image shows a color-coded version of this image; purple represents
residues on the protein which are within 5 angstroms of Haloperidol in one or more of the top 9
most energetically favorable results generated from PyRx AutoDock Vina. The bottom left image
shows the cartoon model version of these interactions.
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Figure 33. Nsp6 vs Haloperidol most energetically favorable result generated by PyRx
AutoDock Vina (predicted molecular docking energy: -7.3 kcal/mol); images generated by
PyMOL. Different regions of purple indicate the top 9 most energetically favorable docking
locations predicted by PyRx AutoDock Vina.
Top Left: Surface model created by PyMOL based on predictions from PyRx
AutoDock Vina (Nsp6: blue; Haloperidol: green)
Top Right: Surface model created by PyMOL of based on predictions from
PyRx AutoDock Vina showing amino acids (purple) within 5 angstroms of
Haloperidol (green)
Bottom Left: Cartoon model model created by PyMOL of based on predictions
generated by PyRx AutoDock Vina showing amino acids (purple) within 5
angstroms of Haloperidol (green)

Famotidine
Figure 34 shows the PyMOL-generated images of the most energetically favorable Nsp6 vs
Famotidine (green) small molecule docking prediction made by PyRx AutoDock Vina; the
estimated binding energy was -5.1 kcal/mol. The top left image shows the general surface model
of the most energetically favorable computationally predicted docking of Famotidine (green) to
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Nsp5 (blue). The top right image shows a color-coded version of this image; pink represents
residues on the protein which are within 5 angstroms of Famotidine in one or more of the top 9
most energetically favorable results generated from PyRx AutoDock Vina. The bottom left image
shows the cartoon model version of these interactions.

Figure 34. Nsp6 vs Famotidine most energetically favorable result generated by PyRx
AutoDock Vina (predicted molecular docking energy: -5.1 kcal/mol); image generated by
PyMOL. Different regions of pink indicate the top 9 most energetically favorable docking
locations predicted by PyRx AutoDock Vina.
Top Left: Surface model created by PyMOL based on predictions from PyRx
AutoDock Vina (Nsp6: blue; Famotidine: green)
Top Right: Surface model created by PyMOL of based on predictions from
PyRx AutoDock Vina showing amino acids (pink) within 5 angstroms of
Famotidine (green)
Bottom Left: Cartoon model model created by PyMOL of based on predictions
generated by PyRx AutoDock Vina showing amino acids (pink) within 5
angstroms of Famotidine (green)
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Molnupiravir
Figure 35 shows the PyMOL-generated images of the most energetically favorable Nsp6 vs
Molnupiravir (green) small molecule docking prediction made by PyRx AutoDock Vina; the
estimated binding energy was -6.6 kcal/mol. The top left image shows the general surface model
of the most energetically favorable computationally predicted docking of Molnupiravir (green) to
Nsp6 (blue). The top right image shows a color-coded version of this image; purple represents
residues on the protein which are within 5 angstroms of Molnupiravir in one or more of the top 9
most energetically favorable results generated from PyRx AutoDock Vina. The bottom left image
shows the cartoon model version of these interactions.
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Figure 35: Nsp6 vs Molnupiravir most energetically favorable result generated by PyRx
AutoDock Vina (predicted molecular docking energy: -6.6 kcal/mol); images generated by
PyMOL. Different regions of purple indicate the top 9 most energetically favorable docking
locations predicted by PyRx AutoDock Vina.
Top Left: Surface model created by PyMOL based on predictions from PyRx
AutoDock Vina (Nsp6: blue; Molnupiravir: green)
Top Right: Surface model created by PyMOL of based on predictions from
PyRx AutoDock Vina showing amino acids (purple) within 5 angstroms of
Molnupiravir (green)
Bottom Left: Cartoon model model created by PyMOL of based on predictions
generated by PyRx AutoDock Vina showing amino acids (pink) within 5
angstroms of Molnupiravir (green)

Cardiac Myosin vs Nsp5: Corrected
After going through the results of this study, we realized that the version of Cardiac Myosin we
used was tagged with GFP and that GFP was involved in some of the interactions we were
seeing; thus, we removed GFP and re-did these interactions; the results are shown below. The
recalculated protein-protein interactions are also present in Table 3.
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The ClusPro Model Score for the Cardiac Myosin-Nsp5 complex with the GFP tag removed
(Figure 36) was -201.4.

Figure 36: Cardiac Myosin (green) – Nsp5 (blue) complex predicted by ClusPro and
visualized using PyMOL (amino acids on Cardiac Myosin within 5 angstroms of Nsp5 are
shown in pink, amino acids on Nsp5 within 5 angstroms of Cardiac Myosin are shown in
orange)
Left: Surface model visualized in PyMOL based on predictions from ClusPro
Right: Cartoon model visualized in PyMOL based on predictions from ClusPro
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Figure 37 below shows labeled regions of cardiac myosin for use in comparing to where
potential interactions might take place.

Figure 37: Labeled regions of cardiac myosin. From “Multidimensional structure-function
relationships in human β-cardiac myosin from population-scale genetic variation” by
Homburger, J. R., et al., 2016, Proc Natl Acad Sci U S A 113(24), pp. 6701-6706.

Valproic Acid
Figure 38 shows the PyMOL-generated images of the most energetically favorable Cardiac
Myosin (Without GFP Tag)-Nsp5 complex vs Valproic Acid small molecule docking prediction
made by PyRx AutoDock Vina; the estimated binding affinity was -4.5 kcal/mol.
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Figure 38: Cardiac Myosin (Without GFP Tag)-Nsp5 complex (pink and blue) vs Valproic
Acid (green) most energetically favorable result predicted by PyRx AutoDock Vina (predicted
molecular docking energy: -4.5 kcal/mol); cardiac myosin-Nsp5 complex predicted via
ClusPro and images generated by PyMOL. Different regions of pink indicate the top 9 most
energetically favorable docking locations predicted by PyRx AutoDock Vina.
Left: Surface model
Right: Cartoon model

Apicidin
Figure 39 shows the PyMOL-generated images of the most energetically favorable Cardiac
Myosin (Without GFP Tag)-Nsp5 complex vs Apicidin small molecule docking prediction made
by PyRx AutoDock Vina; the estimated binding affinity was -7.6 kcal/mol.

Figure 39: Cardiac Myosin (Without GFP Tag)-Nsp5 complex (pink and blue) vs Apicidin
(green) most energetically favorable result generated by PyRx AutoDock Vina (predicted
molecular docking energy: -7.6 kcal/mol); cardiac myosin-Nsp5 complex generated via
ClusPro and images generated by PyMOL. Different regions of pink indicate the top 9 most
energetically favorable docking locations predicted by PyRx AutoDock Vina.
Left: Surface model
Right: Cartoon model
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Famotidine
Figure 40 shows the PyMOL-generated images of the most energetically favorable Cardiac
Myosin (Without GFP Tag)-Nsp5 complex vs Apicidin small molecule docking prediction made
by PyRx AutoDock Vina; the estimated binding affinity was -5.5 kcal/mol.

Figure 40: Cardiac Myosin (Without GFP Tag)-Nsp5 complex (pink and green) vs Famotidine
(blue) most energetically favorable result generated by PyRx AutoDock Vina (predicted
molecular docking energy: -5.5 kcal/mol); cardiac myosin-Nsp5 complex generated via
ClusPro and images generated by PyMOL. Different regions of pink indicate the top 9 most
energetically favorable docking locations predicted by PyRx AutoDock Vina.
Left: Surface model
Right: Cartoon model

Molnupiravir
Figure 41 shows the PyMOL-generated images of the most energetically favorable Cardiac
Myosin (Without GFP Tag)-Nsp5 complex vs Molnupiravir small molecule docking prediction
made by PyRx AutoDock Vina; the estimated binding affinity was -6.2 kcal/mol.
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Figure 41: Cardiac Myosin (Without GFP Tag)-Nsp5 complex (pink and green) vs
Molnupiravir (blue) most energetically favorable result generated by PyRx AutoDock Vina
(predicted molecular docking energy: -6.2 kcal/mol); cardiac myosin-Nsp5 complex generated
via ClusPro and images generated by PyMOL. Different regions of pink indicate the top 9
most energetically favorable docking locations predicted by PyRx AutoDock Vina.
Left: Surface model
Right: Cartoon model

Cardiac Myosin vs Nsp3: Corrected
The average model score for the top 6 VdW + Elec Cardiac Myosin-Nsp3 complexes with GFP
removed computationally predicted by ClusPro was -332.5. Figure 42 shows the predicted
interactions, visualized using PyMOL.
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Figure 42: Cardiac Myosin (green) – Nsp3 (blue) complex predicted by ClusPro and
visualized using PyMOL (amino acids on Cardiac Myosin within 5 angstroms of Nsp5 are
represented by orange, amino acids on Nsp3 within 5 angstroms of Cardiac Myosin are
represented by pink)
Left: Surface model visualized in PyMOL based on predictions from ClusPro
Right: Cartoon model visualized in PyMOL based on predictions from ClusPro

Folic Acid
The predicted interactions for this compound did not involve the GFP tag and thus did not need
to be redone.
Famotidine
The predicted interactions for this compound did not involve the GFP tag and thus did not need
to be redone.

Molnupiravir
The predicted interactions for this compound did not involve the GFP tag and thus did not need
to be redone.
Below is a table summarizing all of the different docking interactions listed above, and their
energies, ranked from most to least favorable.
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Table 4: Energetic Properties of Molecular docking using computational methods Results
Interaction
Most Negative Binding Affinity (kcal/mol)
ATP13A3-Nsp6 Complex vs Haloperidol
-9
ATP13A2- Nsp3 complex vs Molnupiravir
-8.2
ATP13A3-Nsp6 Complex vs Bafilomycin A1 -8.1
Cardiac Myosin-Nsp5 Complex vs
-7.8
Molnupiravir
Cardiac Myosin (Without GFP Tag)-Nsp5
-7.6
Complex vs Apicidin
ATP13A3-Nsp6 Complex vs Molnupiravir
-7.6
Nsp6 vs Bafilomycin A1
-7.4
Nsp6 vs Haloperidol
-7.3
Cardiac Myosin-Nsp5 Complex vs Apicidin
-7.3
Cardiac Myosin-Nsp3 Complex vs
-7.2
Molnupiravir
Nsp3 vs Molnupiravir
-7.0
Nsp5 vs Molnupiravir
-6.7
Nsp6 vs Molnupiravir
-6.6
ATP13A2-Nsp3 Complex vs Famotidine
-6.6
Nsp3 vs Famotidine
-6.3
Nsp3 vs Apicidin
-6.3
Cardiac Myosin (Without GFP Tag)-Nsp5
-6.2
Complex vs Molnupiravir
Cardiac Myosin-Nsp3 Complex vs
-6.2
Famotidine
ATP13A3-Nsp6 Complex vs Famotidine
-6.0
ATP13A2-Nsp3 Complex vs Folic Acid
-5.7
Cardiac Myosin-Nsp5 Complex vs
-5.6
Famotidine
Cardiac Myosin (Without GFP Tag)-Nsp5
-5.5
Complex vs Famotidine
Nsp5 vs Famotidine
-5.4
Nsp6 vs Famotidine
-5.1
Cardiac Myosin-Nsp5 Complex vs Valproic
-5.1
Acid
Nsp3 vs Folic Acid
-4.8
Cardiac Myosin-Nsp3 Complex vs Folic Acid -4.6
Cardiac Myosin (Without GFP Tag)-Nsp5
-4.5
Complex vs Valproic Acid
Nsp5 vs Valproic Acid
-4.2
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DISCUSSION
In terms of interactions between COVID nonstructural proteins and human proteins, we found a
surprisingly strong one between ATP13A2 and Nsp3, with a ClusPro model score of -734.3 (Table
3). As suggested earlier, this could point to a potential mechanism in the occurrence of brain fog
and other neurological symptoms seen in some COVID patients by hindering the ability of the
ATPase to carry out its normal functions. Nsp3 was also found to interact strongly with ATP13A3
(-497.8 ClusPro model score) and thus could be a factor in COVID-related pulmonary
hypertension (Table 3). Furthermore, after re-doing cardiac myosin interactions with the GFP tag
removed, Nsp3 also docked moderately favorably with cardiac myosin with a model score of 332.5, suggesting a potential implication in the mechanism of cardiac complications seen in
COVID-patients (Table 3). Nsp3, then, might be an important drug target in the treatment of
COVID-19. However, the risk of developing drugs that works to inhibit a viral protease is that
they can also inhibit the human proteasome and lead to side effects such as dyslipidemia, as has
been found to be the case with some viral protease inhibitors used in the treatment of HIV46.

The compound most of note seen in terms of molecular docking energetics (using computational
methods) may be Haloperidol. It displayed the most favorable interaction among protein-molecule
interactions (Nsp6 vs Haloperidol) at -7.3 kcal/mol as well as the most favorable interaction among
protein-protein-molecule interactions (ATP13A3-Nsp6 complex vs Haloperidol) at -9 kcal/mol
(Table 4, Figure 33). It is important to note that, although the Nsp6-Bafilomycin A1 molecular
docking is technically more favorable at -7.4 kcal/mol, the margin of error in obtaining data like
this likely makes the difference too small to be significant. Regarding Figure 33, showing the
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surface structure of Nsp6 in interaction with Haloperidol (the ATP13A3-Nsp6 complex was too
large to display surface characteristics without losing visibility of the docked molecules), the
molecule appears well-fitted within the predicted molecular docking using computational methods
area, in that the surface curves of the protein and the structure of the molecule as close to parallel
as something of this nature might be. This snug fit suggests a strong interaction between the two
due to more surface area for noncovalent interactions, thus validating the high favorability seen in
their binding energies.

In terms of mutations, the Nsp6 sequence used for the purpose of this study already possessed a
phenylalanine at position 37 (one study found common mutations in Nsp6 of L37F18),
complicating the process of assessing the impact of mutations on protein interactions and
molecular docking, however, based on the protein-protein and protein-molecule interactions
observed in this study, this amino acid position did not appear to be involved. Though this study
is by no means comprehensive, these results suggest that this particular amino acid position is
either not heavily involved in interactions, or that it is involved in interactions not studied here.
Since this protein localizes to the ER membrane, the cause is more likely to be the latter.

We are not necessarily surprised by the high predicted affinities of the currently-in-use antiviral
drugs, such as Molnupiravir, seen in Table 4, nor are we particularly shocked to see lower-value
computational molecular docking affinities in some of the predicted compounds; they are, after
all, only predicted. The true questions moving forward are those that stem from the limitations of
this study. First, the computational models listed in this study are all done via computer algorithms
that are, like their creators, imperfect and do not necessarily accurately represent cellular
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conditions or protein structures. Thus, the first question is if the molecules truly interact with these
proteins in vivo in the way we have observed here, and if they interact at all. Future research should
first focus on observing and confirming these interactions in vitro. To confirm these interactions,
bench research such as pull-down assays, surface plasmon resonance, and Far-Western blots,
among others, are needed.

Another question that emerged during the progress of this study was whether the small molecules
dock in the same locations on their respective proteins, and if so, if they would result in the same
effects in vivo. As seen in Figure 43 below, in Nsp6, potential docking predictions made by PyRx
AutoDock Vina placed Famotidine and Molnupiravir together in one binding pocket and
Haloperidol and Bafilomycin A1 together in another binding pocket. In addition, it is worth asking
whether any of these molecules could be used together to enhance treatment effectiveness.

Figure 43: Nsp6 (light pink) vs Famotidine (blue), Molnupiravir (yellow), Haloperidol
(fuchsia), and Bafilomycin A1 (green)
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The next limitation is that we cannot see or predict for certain what the downstream impacts of
this binding would be. If introduced into a cell, these molecules could bind to and interact with
other drug molecules or proteins and unpredicted cause side effects or harm. Even if they did
interact with cellular proteins in vivo or in vitro in the exact same way that was seen in this study,
we cannot predict with this kind of computational modeling what the result of this would be, and
whether it would lead to a positive or negative outcome.
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CONCLUSIONS AND FUTURE DIRECTIONS
In this study, we wanted to uncover potential interactions between COVID-19 nonstructural
proteins 3, 5, and 6 with human proteins ATP13A2 and ATP13A3, and some potential and current
therapeutic compounds. Thus, the primary result to emerge from this study was the identification
of the presence of potential interactions. Potentially the most intriguing avenue of study opened
by this investigation is the predicted interaction between Nsp3 and ATP13A2. Because of
ATP13A2’s involvement in neurodegenerative diseases and their highly favorable interaction, it
is worth confirming whether this interaction occurs in vivo and examining whether this is a
contributing factor to the Alzheimer’s-like changes seen in some COVID-19 patients’ brains. If
this is implicated as a mechanism of disease, then the next step would likely be figuring out
therapeutic compounds to inhibit Nsp3 activity that have minimal side effects (due to the potential
toxicity of protease inhibitors); the most promising compound studied here in that respect seems
to be Molnupiravir, in a potential off-target interaction.

Regarding general COVID-19 treatment, Haloperidol’s strong interactions warrant further testing
to confirm its predicted interactions in vivo as well as investigation of how it impacts viral
replication.

We hope that the data in this study will provide a foundational basis for future research into the
mechanisms of SARS-CoV-2 infection and symptoms as well as into ways to treat it. While the
spike protein seems to be a major target in developing vaccines due to its importance in entering
the virus by interactions with the ACE2 receptor, it is important to investigate other targets that
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might be more effective or serve as a backup if treatments targeting the spike protein become
ineffective48. There were many promising potential interactions found here that deserve more time
and effort into verifying their impacts in living cells and that, if they occur, could provide useful
treatment targets.
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APPENDIX A
2D Chemical Structures of Potentially Therapeutic Compounds37

Apicidin

Bafilomycin A1

Famotidine

Folic Acid

69

Haloperidol

Molnupiravir

Valproic Acid
Figure 44: Chemical Structures of Potentially Therapeutic Compounds
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APPENDIX B
Protein sequences
Protein

Sequence

Nsp336

APTKVTFGDDTVIEVQGYKSVNITFELDERIDKVLNEKCSAYTVELGTEVNEFACVVADAVIKTLQPVSELLTPLGID
LDEWSMATYYLFDESGEFKLASHMYCSFYPPDEDEEEGDCEEEEFEPSTQYEYGTEDDYQGKPLEFGATSAALQPEEE
QEEDWLDDDSQQTVGQQDGSEDNQTTTIQTIVEVQPQLEMELTPVVQTIEVNSFSGYLKLTDNVYIKNADIVEEAKKV
KPTVVVNAANVYLKHGGGVAGALNKATNNAMQVESDDYIATNGPLKVGGSCVLSGHNLAKHCLHVVGPNVNKGEDIQL
LKSAYENFNQHEVLLAPLLSAGIFGADPIHSLRVCVDTVRTNVYLAVFDKNLYDKLVSSFLEMKSEKQVEQKIAEIPK
EEVKPFITESKPSVEQRKQDDKKIKACVEEVTTTLEETKFLTENLLLYIDINGNLHPDSATLVSDIDITFLKKDAPYI
VGDVVQEGVLTAVVIPTKKAGGTTEMLAKALRKVPTDNYITTYPGQGLNGYTVEEAKTVLKKCKSAFYILPSIISNEK
QEILGTVSWNLREMLAHAEETRKLMPVCVETKAIVSTIQRKYKGIKIQEGVVDYGARFYFYTSKTTVASLINTLNDLN
ETLVTMPLGYVTHGLNLEEAARYMRSLKVPATVSVSSPDAVTAYNGYLTSSSKTPEEHFIETISLAGSYKDWSYSGQS
TQLGIEFLKRGDKSVYYTSNPTTFHLDGEVITFDNLKTLLSLREVRTIKVFTTVDNINLHTQVVDMSMTYGQQFGPTY
LDGADVTKIKPHNSHEGKTFYVLPNDDTLRVEAFEYYHTTDPSFLGRYMSALNHTKKWKYPQVNGLTSIKWADNNCYL
ATALLTLQQIELKFNPPALQDAYYRARAGEAANFCALILAYCNKTVGELGDVRETMSYLFQHANLDSCKRVLNVVCKT
CGQQQTTLKGVEAVMYMGTLSYEQFKKGVQIPCTCGKQATKYLVQQESPFVMMSAPPAQYELKHGTFTCASEYTGNYQ
CGHYKHITSKETLYCIDGALLTKSSEYKGPITDVFYKENSYTTTIKPVTYKLDGVVCTEIDPKLDNYYKKDNSYFTEQ
PIDLVPNQPYPNASFDNFKFVCDNIKFADDLNQLTGYKKPASRELKVTFFPDLNGDVVAIDYKHYTPSFKKGAKLLHK
PIVWHVNNATNKATYKPNTWCIRCLWSTKPVETSNSFDVLKSEDAQGMDNLACEDLKPVSEEVVENPTIQKDVLECNV
KTTEVVGDIILKPANNSLKITEEVGHTDLMAAYVDNSSLTIKKPNELSRVLGLKTLATHGLAAVNSVPWDTIANYAKP
FLNKVVSTTTNIVTRCLNRVCTNYMPYFFTLLLQLCTFTRSTNSRIKASMPTTIAKNTVKSVGKFCLEASFNYLKSPN
FSKLINIIIWFLLLSVCLGSLIYSTAALGVLMSNLGMPSYCTGYREGYLNSTNVTIATYCTGSIPCSVCLSGLDSLDT
YPSLETIQITISSFKWDLTAFGLVAEWFLAYILFTRFFYVLGLAAIMQLFFSYFAVHFISNSWLMWLIINLVQMAPIS
AMVRMYIFFASFYYVWKSYVHVVDGCNSSTCMMCYKRNRATRVECTTIVNGVRRSFYVYANGGKGFCKLHNWNCVNCD
TFCAGSTFISDEVARDLSLQFKRPINPTDQSSYIVDSVTVKNGSIHLYFDKAGQKTYERHSLSHFVNLDNLRANNTKG
SLPINVIVFDGKSKCEESSAKSASVYYSQLMCQPILLLDQALVSDVGDSAEVAVKMFDAYVNTFSSTFNVPMEKLKTL
VATAEAELAKNVSLDNVLSTFISAARQGFVDSDVETKDVVECLKLSHQSDIEVTGDSCNNYMLTYNKVENMTPRDLGA
CIDCSARHINAQVAKSHNIALIWNVKDFMSLSEQLRKQIRSAAKKNNLPFKLTCATTRQVVNVVTTKIALKGG

Nsp536

SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIRKSNHNFLVQAGNVQLRVI
GHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDC
VSFCYMHHMELPTGVHAGTDLEGNFYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVA
MKYNYEPLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ

Nsp636

SAVKRTIKGTHHWLLLTILTSLLVLVQSTQWSLFFFLYENAFLPFAMGIIAMSAFAMMFVKHKHAFLCLFLLPSLATV
AYFNMVYMPASWVMRIMTWLDMVDTSLSGFKLKDCVMYASAVVLLILMTARTVYDDGARRVWTLMNVLTLVYKVYYGN
ALDQAISMWALIISVTSNYSGVVTTVMFLARGIVFMCVEYCPIFFITGNTLQCIMLVYCFLGYFCTCYFGLFCLLNRY
FRLTLGVYDYLVSTQEFRYMNSQGLLPPKNSIDAFKLNIKLLGVGGKPCIKVATVQ

ATP13A210

MSADSSPLVGSTPTGYGTLTIGTSIDPLSSSVSSVRLSGYCGSPWRVIGYHVVVWMMAGIPLLLFRWKPLWGVRLRLR
PCNLAHAETLVIEIRDKEDSSWQLFTVQVQTEAIGEGSLEPSPQSQAEDGRSQAAVGAVPEGAWKDTAQLHKSEEAVS
VGQKRVLRYYLFQGQRYIWIETQQAFYQVSLLDHGRSCDDVHRSRHGLSLQDQMVRKAIYGPNVISIPVKSYPQLLVD
EALNPYYGFQAFSIALWLADHYYWYALCIFLISSISICLSLYKTRKQSQTLRDMVKLSMRVCVCRPGGEEEWVDSSEL
VPGDCLVLPQEGGLMPCDAALVAGECMVNESSLTGESIPVLKTALPEGLGPYCAETHRRHTLFCGTLILQARAYVGPH
VLAVVTRTGFCTAKGGLVSSILHPRPINFKFYKHSMKFVAALSVLALLGTIYSIFILYRNRVPLNEIVIRALDLVTVV
VPPALPAAMTVCTLYAQSRLRRQGIFCIHPLRINLGGKLQLVCFDKTGTLTEDGLDVMGVVPLKGQAFLPLVPEPRRL
PVGPLLRALATCHALSRLQDTPVGDPMDLKMVESTGWVLEEEPAADSAFGTQVLAVMRPPLWEPQLQAMEEPPVPVSV
LHRFPFSSALQRMSVVVAWPGATQPEAYVKGSPELVAGLCNPETVPTDFAQMLQSYTAAGYRVVALASKPLPTVPSLE
AAQQLTRDTVEGDLSLLGLLVMRNLLKPQTTPVIQALRRTRIRAVMVTGDNLQTAVTVARGCGMVAPQEHLIIVHATH
PERGQPASLEFLPMESPTAVNGVKDPDQAASYTVEPDPRSRHLALSGPTFGIIVKHFPKLLPKVLVQGTVFARMAPEQ
KTELVCELQKLQYCVGMCGDGANDCGALKAADVGISLSQAEASVVSPFTSSMASIECVPMVIREGRCSLDTSFSVFKY
MALYSLTQFISVLILYTINTNLGDLQFLAIDLVITTTVAVLMSRTGPALVLGRVRPPGALLSVPVLSSLLLQMVLVTG
VQLGGYFLTLAQPWFVPLNRTVAAPDNLPNYENTVVFSLSSFQYLILAAAVSKGAPFRRPLYTNVPFLVALALLSSVL
VGLVLVPGLLQGPLALRNITDTGFKLLLLGLVTLNFVGAFMLESVLDQCLPACLRRLRPKRASKKRFKQLERELAEQP
WPPLPAGPLR
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ATP13A310

MDREERKTINQGQEDEMEIYGYNLSRWKLAIVSLGVICSGGFLLLLLYWMPEWRVKATCVRAAIKDCEVVLLRTTDEF
KMWFCAKIRVLSLETYPVSSPKSMSNKLSNGHAVCLIENPTEENRHRISKYSQTESQQIRYFTHHSVKYFWNDTIHNF
DFLKGLDEGVSCTSIYEKHSAGLTKGMHAYRKLLYGVNEIAVKVPSVFKLLIKEVLNPFYIFQLFSVILWSTDEYYYY
ALAIVVMSIVSIVSSLYSIRKQYVMLHDMVATHSTVRVSVCRVNEEIEEIFSTDLVPGDVMVIPLNGTIMPCDAVLIN
GTCIVNESMLTGESVPVTKTNLPNPSVDVKGIGDELYNPETHKRHTLFCGTTVIQTRFYTGELVKAIVVRTGFSTSKG
QLVRSILYPKPTDFKLYRDAYLFLLCLVAVAGIGFIYTIINSILNEVQVGVIIIESLDIITITVPPALPAAMTAGIVY
AQRRLKKIGIFCISPQRINICGQLNLVCFDKTGTLTEDGLDLWGIQRVENARFLSPEENVCNEMLVKSQFVACMATCH
SLTKIEGVLSGDPLDLKMFEAIGWILEEATEEETALHNRIMPTVVRPPKQLLPESTPAGNQEMELFELPATYEIGIVR
QFPFSSALQRMSVVARVLGDRKMDAYMKGAPEAIAGLCKPETVPVDFQNVLEDFTKQGFRVIALAHRKLESKLTWHKV
QNISRDAIENNMDFMGLIIMQNKLKQETPAVLEDLHKANIRTVMVTGDSMLTAVSVARDCGMILPQDKVIIAEALPPK
DGKVAKINWHYADSLTQCSHPSAIDPEAIPVKLVHDSLEDLQMTRYHFAMNGKSFSVILEHFQDLVPKLMLHGTVFAR
MAPDQKTQLIEALQNVDYFVGMCGDGANDCGALKRAHGGISLSELEASVASPFTSKTPSISCVPNLIREGRAALITSF
CVFKFMALYSIIQYFSVTLLYSILSNLGDFQFLFIDLAIILVVVFTMSLNPAWKELVAQRPPSGLISGALLFSVLSQI
IICIGFQSLGFFWVKQQPWYEVWHPKSDACNTTGSGFWNSSHVDNETELDEHNIQNYENTTVFFISSFQYLIVAIAFS
KGKPFRQPCYKNYFFVFSVIFLYIFILFIMLYPVASVDQVLQIVCVPYQWRVTMLIIVLVNAFVSITVEESVDRWGKC
CLPWALGCRKKTPKAKYMYLAQELLVDPEWPPKPQTTTEAKALVKENGSCQIITIT

Cardiac
Myosin10

MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQ
QNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFS
ISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAK
TVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAF
ISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGL
NSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIF
DFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDM
TFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANY
AGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGI
RICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDER
LSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTR
LKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAEL
TAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEE
DKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNA
RIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAE
FQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKM
CRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAK
NALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAV
EAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELF
KLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILR
AQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAE
AQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLL
HSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQ
HRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQ
LKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE

F-actin10

DEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIITN
WDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREKMTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSG
DGVTHNVPIYEGYALPHAIMRLDLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSS
SLEKSYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNVMSGGTTMYPGIADR
MQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWITKQEYDEAGPSIVHRKCF
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APPENDIX C
Labeled ATPases
ATP13A2
This picture below shows the interaction of ATP13A2 with Nsp3 to illustrate the regions of
ATP13A2.The transmembrane helices are shown in orange. The N domain is shown in white and
the P domain in dark blue, between which the interaction of ADP occurs (following the binding of
ATP that results in the N domain twisting closer to the P domain)47. The regions where potential
interactions predicted by PyRx AutoDock Vina are shown in yellow for Molnupiravir, pink for
Folic Acid, and light blue for Famotidine (although there may be regions not shown for each of
these due to the inability to showcase multiple colors at once).

Figure 45: Regions of ATP13A2 visualized using PyMOL (Dark blue: P domain; white: N
domain; orange: transmembrane domains). Small molecule docking interactions predicted by
PyRx AutoDock Vina are also shown (pink: Folic Acid; yellow: Molnupiravir; light blue:
Famotidine).
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ATP13A3
The picture below shows the interaction of ATP13A3 to Nsp6 to illustrate the regions of
ATP13A3. The transmembrane helices are shown in orange10. The region which interacts with
ATP is shown in red10. The regions where potential interactions predicted by PyRx AutoDock
Vina are shown in yellow (Haloperidol), white (Molnupiravir), pink (Famotidine), and light blue
(Bafilomycin A1).

Figure 46: Regions of ATP13A3 visualized using PyMOL (orange: transmembrane domains,
red: ATP-interacting). Small molecule docking interactions predicted by PyRx AutoDock
Vina are also shown (pink: Famotidine; light blue: Bafilomycin A1; yellow: Haloperidol;
white: Molnupiravir).
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